Janssen Biotech is paying refunds for overcharges on certain 340B drugs purchased in the third quarter of 2020.

Janssen Issuing Refunds for 340B Overcharges

Drug manufacturer Janssen Biotech recently determined that it owes or may owe refunds to some 340B covered entities. The refunds [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.